8-K: STAAR Surgical Announces $30 Million Share Repurchase Program and China Regulatory Approval for EVO+ Toric ICL

STAAR Surgical's Board of Directors has authorized a $30 million share repurchase program, and the company has received regulatory approval in China for its EVO+ Toric Implantable Collamer Lens (EVO+ TICL).

Summary

• STAAR Surgical Company announced a share repurchase program authorized by its Board of Directors, allowing the company to repurchase up to $30 million of its outstanding common stock.
• The company may repurchase shares through various methods, including open market purchases, privately negotiated transactions, structured repurchase agreements, block purchases, and Rule 10b5-1 trading plans.
• The timing, manner, price, and amount of repurchases will be determined by the company at its discretion, subject to market conditions and legal requirements.
• STAAR Surgical is not obligated to repurchase any specific number of shares, and the program may be modified, suspended, or discontinued at any time.
• The share repurchase program is expected to continue over the next six months, unless extended or shortened by the Board of Directors.
• The company intends to fund repurchases from cash on hand and cash generated from operations.
• As of March 28, 2025, STAAR Surgical had $222.8 million in cash, cash equivalents, and investments available for sale, with no outstanding debt.
• The company had approximately 49.5 million shares of common stock outstanding as of March 28, 2025.
• The National Medical Products Administration (NMPA) in China approved the company's EVO+ Toric Implantable Collamer Lens (EVO+ TICL) for marketing and sale in China on May 14, 2025.
• The EVO+ TICL is indicated for use in phakic eye treatment in patients 21-45 years of age for the correction and reduction of myopia in patients ranging from -0.5D to -18.0D with less than or equal to 6.0D of astigmatism.
• STAAR Surgical has been marketing and selling its EVO ICL (toric and spheric) in China since 2014.
• The EVO+ ICL, which has a larger optical zone than the EVO ICL, was approved by the U.S. FDA in March 2022.
• The company has also submitted an application with the NMPA for its EVO+ spheric ICL, which remains pending.
• STAAR Surgical is working to ready its Switzerland manufacturing facility for production of EVO and EVO+ ICLs for marketing and sale in China, subject to manufacturing validations and required approvals.

Sentiment

Score: 8

Explanation: The announcement is positive due to the share repurchase program and regulatory approval in China, indicating confidence in the company's future prospects and growth potential. The strong cash position and lack of debt further contribute to the positive sentiment.

Positives

• The share repurchase program signals management's confidence in STAAR's future and ability to return to profitable growth.
• STAAR Surgical has a strong balance sheet with significant cash reserves and no debt.
• The China regulatory approval for EVO+ Toric ICL expands the company's market opportunity in China.
• The EVO+ ICL has a larger optical zone than the EVO ICL, potentially offering improved patient outcomes.
• The company's Switzerland manufacturing facility is being prepared for production of ICLs for the Chinese market.

Negatives

• The share repurchase program is discretionary and may be modified, suspended, or discontinued at any time.
• The company's ability to produce ICLs in Switzerland for China is subject to manufacturing validations and receipt of all required approvals.
• The application with the NMPA for its EVO+ spheric ICL remains pending.

Risks

• The timing, manner, price, and amount of any repurchases under the program will be determined by STAAR in its discretion, subject to market conditions, legal requirements, and other considerations.
• Uncertainties exist regarding the market price of STAAR's common stock.
• The company's ability to continue its growth and profitability trajectory is not guaranteed.
• The company relies on independent distributors in international markets.
• A slowdown or disruption to the Chinese economy could impact sales.
• Global economic conditions and disruptions in the supply chain pose risks.
• Fluctuations in foreign currency exchange rates could affect financial results.
• International trade disputes and dependence on demand from Asia create risks.
• Changes in effective tax rate or tax laws could impact profitability.
• Loss of use of the principal manufacturing facility could disrupt operations.
• Competition in the market could affect sales and market share.
• Potential losses due to product liability claims exist.
• The company is exposed to environmental liability.
• Data corruption, cyber-based attacks, or network security breaches could disrupt operations.
• The willingness of surgeons and patients to adopt new products and procedures is uncertain.
• Extensive clinical trials and resources are devoted to research and development.
• Compliance with government regulations is required.
• Regulatory agencies have the discretion to approve or reject products.
• Laws pertaining to healthcare fraud and abuse pose risks.
• Changes in FDA or international regulations could impact product approval.
• Product recalls or failures could occur.

Future Outlook

The share repurchase program is expected to continue over the next six months, unless extended or shortened by the Board of Directors. The company intends to fund repurchases under this share repurchase program from cash on hand and cash generated from operations.

Management Comments

• 'Our decision to initiate a share repurchase program underscores the Board's and management's confidence in STAAR's future and our ability to return to sustainable, profitable growth,' said Stephen C. Farrell, Chief Executive Officer of STAAR Surgical.
• Management believes STAAR shares represent an attractive investment, and this repurchase program demonstrates their belief in the intrinsic value of STAAR shares.

Industry Context

The announcement reflects a broader trend of companies with strong balance sheets returning capital to shareholders through share repurchase programs. The China regulatory approval is significant as China represents a large and growing market for vision correction procedures.

Comparison to Industry Standards

• Other ophthalmic companies such as Alcon and Johnson & Johnson Vision also focus on vision correction solutions, but STAAR Surgical differentiates itself with its exclusive focus on implantable collamer lenses.
• The $30 million share repurchase program is relatively small compared to larger companies in the medical device industry, but it is a significant move for a company of STAAR's size.
• The EVO+ ICL approval in China positions STAAR to compete with other refractive surgery options like LASIK and SMILE, offering a potentially less invasive alternative.

Stakeholder Impact

• Shareholders may benefit from the share repurchase program, which could increase earnings per share and potentially boost the stock price.
• Employees may feel more secure knowing the company is financially stable and confident in its future.
• Customers in China will have access to the EVO+ Toric ICL, providing an additional vision correction option.
• Suppliers may benefit from increased production and sales of ICLs.
• Creditors are not directly impacted as the company has no debt.

Next Steps

• STAAR Surgical will execute the share repurchase program over the next six months, subject to market conditions and other considerations.
• The company will continue to work towards manufacturing validations and required approvals for its Switzerland facility to produce ICLs for the Chinese market.
• STAAR Surgical will await the NMPA's decision on its application for the EVO+ spheric ICL.

Key Dates

Keywords

STAAR Surgical, Share Repurchase, EVO ICL, EVO+ TICL, China, Regulatory Approval, Ophthalmology, Vision Correction, Implantable Collamer Lens